X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Matthew Norawong

Matthew Norawong is a public affairs manager at PhRMA focusing on scientific and regulatory communications. Prior to joining PhRMA, Matthew was a health policy analyst at National Journal’s Network Science Initiative where he primarily supported companies across the biopharmaceutical industry with policy analysis, partnership identification, and messaging strategy. Matthew completed his undergraduate studies in political science at the University of Washington and subsequently earned a Master of Public Health from the George Washington University. A native of the Pacific Northwest, Matthew currently resides in Washington, DC. In his personal time, Matthew enjoys playing bass guitar, competing in amateur DC sports leagues, and exploring new neighborhoods in the DMV area.

Recent Posts

New Report: More than 160 medicines in development for mental illness

By Matthew Norawong  |    January 26, 2023
Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder,...   Read More

ICYMI: Cancer death rate continues to decline due to treatment advances

By Matthew Norawong  |    January 25, 2023
Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...   Read More

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

By Matthew Norawong  |    December 1, 2022
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...   Read More

New Report: Nearly 800 medicines in development to treat chronic conditions

By Matthew Norawong  |    September 29, 2022
Chronic conditions impose a substantial health and economic burden that affects millions of patients, families and communities across the United States each day. While these conditions come with...   Read More

ICYMI: Patients across the country are sharing concerns about government price setting

By Matthew Norawong  |    August 3, 2022
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local...   Read More

ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free

By Matthew Norawong  |    May 25, 2022
Recently, NBC News’ Today did a profile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the...   Read More

Ensuring timely reauthorization of PDUFA and BsUFA

By Matthew Norawong  |    May 11, 2022
Today, the House Energy and Commerce Subcommittee on Health will be hosting a markup session on the comprehensive legislative package to reauthorize the human drug user fee programs, including the...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates